Showing results (41-50 of 62) with videos related to
Sort By:
Pageof 7
European Urology|September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A StudyEvan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.European Urology Oncology|November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 StudyEvan Y Yu, William R Berry, Howard Gurney, et al.Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.Lancet (London, England)|September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialMichael J Morris, Daniel Castellano, Ken Herrmann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.European Urology|April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B StudyEvan Y Yu, Michael P Kolinsky, William R Berry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.International Journal of Cancer|June 15, 2019
New perspectives on screening and early detection of endometrial cancerLaura Costas, Jon Frias-Gomez, Magdalena Guardiola, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.Genome Research|September 22, 2021
A single-cell tumor immune atlas for precision oncologyPaula Nieto, Marc Elosua-Bayes, Juan L Trincado, et al.Pageof 7